Skip to content

Exploring the Application Efficacy of Artificial Intelligence (AI) Diagnostic Tools in Medical Imaging (MI) of Respiratory(R) Infectious (I) Disease (D)

Exploring the Application Efficacy of Artificial Intelligence (AI) Diagnostic Tools in Medical Imaging (MI) of Respiratory(R) Infectious (I) Disease (D)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06553911
Acronym
AI-MIRID
Enrollment
2000
Registered
2024-08-14
Start date
2022-04-01
Completion date
2026-12-01
Last updated
2024-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Artificial Intelligence, Medical Imaging, Respiratory Infectious Diseases

Brief summary

The early identification and severe warning of acute respiratory infectious diseases are of paramount importance. Utilizing effective means to make correct diagnoses of the source of infection at an early stage is the premise of all effective measures. AI-MID is a research initiative that uses artificial intelligence tools to assist in the clinical medical imaging diagnosis of respiratory diseases, aiming to reduce the time doctors spend reviewing images, increase work efficiency, and enhance the sensitivity and specificity of pneumonia detection, thereby improving the detection rate of pneumonia at the grassroots level. This approach facilitates precise prevention, accurate diagnosis, and precise treatment.

Interventions

OTHERArtificial Intelligence-based medical imaging interpretation

In the AI interpretation group, using clinical information, imaging data, and corresponding etiological results of the study participants, an AI diagnostic tool is established to specifically recognize patients' chest medical imaging and construct corresponding diagnostic conclusions.

Sponsors

Huashan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

1. 1-90 years old, gender not specified. 2. Exhibits symptoms of respiratory tract infection 3. Must have etiological examination results 4. Must have imaging data;

Exclusion criteria

1. Severe artifacts in medical images 2. Clinical diagnosis indicates concurrent pulmonary edema 3. Dual review results in unclear diagnosis or potential misdiagnosis 4. Other situations that may cause difficulties in reading the films, or as determined by the researcher, the study participant is deemed unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frameDescription
Evaluating the Diagnostic Efficacy of Artificial Intelligence Diagnostic Tools in Medical Imaging of Respiratory Infectious Diseases2 yearsTo evaluate the diagnostic efficacy of computer-aided detection (CAD) software in the identification of pulmonary infections, the study will employ the following methods: Imaging Criteria: Experienced radiologists will interpret the medical imaging of study participants, serving as the imaging standard. Computer-Aided Detection: Concurrently, the CAD software will analyze the participants' medical imaging to generate diagnostic results. Efficacy Assessment: The accuracy and consistency of the CAD software will be evaluated by comparing its interpretations with the diagnoses made by the radiologists.

Secondary

MeasureTime frameDescription
Utilizing artificial intelligence tools for early identification and severe warning of respiratory infectious diseases2 yearsBy integrating the medical imaging of study participants with the corresponding respiratory pathogen detection results, these data will be used as the training set input into the AI diagnostic tool, enabling it to undergo deep learning. This process will establish an AI diagnostic tool based on pathogen imaging. After completing the data collection for both retrospective and prospective study sections, we plan to evaluate the disease progression and prognosis of the study participants based on survival analysis and predictive modeling. By integrating clinical data and imaging data, we aim to enhance the accuracy and precision of the prognostic assessment model. The model will be continuously optimized according to the changes in the conditions of study participants enrolled over different time periods.

Countries

China

Contacts

Primary ContactWenhong Zhang
zhangwenhong@fudan.edu.cn(86)52889999

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026